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Abstract
Heparin and its low molecular weight derivatives are clinical therapeutics used to treat and prevent
blood clots, but are prone to side effects and contamination. Here we describe the design and
expedient synthesis of heparin-based glycopolymers that are potent and potentially safer mimetics
of heparin. The mimetics exhibited strong activity against proteases in the coagulation cascade and
prolonged blood clot times in human plasma with efficacies similar to those of clinical
anticoagulants.
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Heparin, a heterogeneously sulfated glycosaminoglycan, has been used as an anticoagulant
drug for over 80 years. Although it is a highly effective and inexpensive agent, heparin in its
unfractionated form has several limitations as a therapeutic. First, it is extracted from
porcine or bovine mucosa and tissue and carries the potential risk of contamination. The
global distribution of contaminated heparin in 2007, for example, resulted in over 100 deaths
and hundreds of additional cases reporting adverse clinical effects.[1] Second, heparin
displays a variable dose-response relationship among patients, in part due to its structural
heterogeneity, and thus often requires active monitoring to fine-tune the dosages.[2] Lastly,
approximately 3% of patients undergoing prolonged heparin therapy experience heparin-
induced thrombocytopenia (HIT),[3] a severe autoimmune response triggered by formation
of a complex between heparin and platelet factor 4 (PF4). Altogether, these factors
underscore the critical need to develop safer alternatives to animal-derived heparin that have
more predictable bioactivity and reduced side effects.
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In recent decades, two forms of heparin-based anticoagulants have emerged as alternatives
to unfractionated heparin. Low molecular weight heparin (LMWH) is produced by chemical
or enzymatic degradation of heparin, yielding fragments with an average molecular weight
of 6000 Da.[4] Shorter ultralow molecular weight heparin (ULMWH; ~1500 Da) is prepared
by synthesis[5] of a specific heparin pentasaccharide that represents the minimal epitope
required for antithrombin III (ATIII) activation.[6] The commercial drug Arixtra
(GlaxoSmithKline; Scheme 1) is a methylated derivative of this pentasaccharide. Addition
of another 3-O-sulfate group has been shown to confer even greater specificity for ATIII
activation (Org31550; Scheme 1).[7] For the prophylaxis and treatment of thromboembolic
diseases, LMW and ULMW heparins are preferred over unfractionated heparin due to their
more predictable pharmacokinetics, longer half-lives, and reduced risk of side effects.[3]
However, animal-derived LMWH still has considerable structural heterogeneity and is
susceptible to external contamination.[1b] ULMWH is notoriously difficult and expensive to
synthesize (~ 50 chemical steps, ~ 0.1% overall yield in the case of Arixtra)[5a,b] and
exhibits limited inhibitory activity toward thrombin (also known as Factor IIa (FIIa)) due to
its shorter length.[5a] Thus, despite the notable advantages of LMW and ULMW heparins,
new methods are greatly needed for the efficient preparation of defined heparin-like
molecules with broad anticoagulation profiles and improved safety.
Synthetic glycopolymers[8] bearing short, well-defined heparin epitopes may offer an
attractive alternative to natural heparins and Arixtra. Here, we utilize ring-opening
metathesis polymerization (ROMP)[9] chemistry to generate a series of heparin-based
glycopolymers and demonstrate that their structures can be tailored to recapitulate the potent
activity of anticoagulant drugs. Previously, we showed that glycopolymers containing
defined chondroitin sulfate (CS) di- and tetrasaccharide[10] and heparan sulfate (HS)
disaccharide[11] epitopes could mimic the activity of natural glycosaminoglycans in neurite
outgrowth[10] and immune cell migration[11] assays, respectively. However, the application
of ROMP to heparin, the most highly charged and synthetically challenging
glycosaminoglycan, has not been investigated. Moreover, synthetic glycopolymers with
medicinally significant anticoagulant activity have not been extensively explored as
potential heparin mimetics. Our approach overcomes the challenges of heterogeneous
sulfation and complex oligosaccharide synthesis and shows promise for the development of
a new class of medicinal agents.
The first challenge in designing an anticoagulant glycopolymer was to select a minimal unit
that encapsulated the key determinants of the ATIII-binding pentasaccharide. Although
previous studies had suggested that a pentasaccharide was the minimum active motif,[5,6] we
reasoned that a disaccharide epitope might be sufficient when presented on a multivalent,
polymeric scaffold that might enable enhancement of its binding affinity through avidity.[12]
Thus, we chose two monosaccharide units (G and H, Scheme 1) from the reducing end of
the pentasaccharide, given their well-characterized interactions with the A-helix (R46, R47)
and P-helix (K114, D113) of ATIII.[13] The inclusion of unit G allowed us to exploit the
conformational flexibility of L-iduronic acid, which substantially improves the affinity of
heparin for ATIII.[14] We chose unit H of Org31550 because it contains a rare 3-O-sulfate
modification that significantly enhances the interaction of heparin with ATIII.[7]
Glycopolymer 1, comprised of units G and H, can be readily derived from disaccharide 3
(Scheme 2). We devised a protecting group strategy for 3 that would allow for expedient
sulfation at four different sites. A benzoyl (Bz) group was used to protect C3, and acetyl
(Ac) groups were selected to protect the C2’ and C6 positions. These groups can be removed
under the same conditions required for C5’ saponification[15] to expose simultaneously the
three sites desired for O-sulfation. In addition, the C2’ Ac group was expected to facilitate
formation of the 1,2-trans glycosidic linkage through neighboring group participation. Due
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to the highly charged nature of the sulfated monomer required for polymerization, we
elected to use benzyl (Bn) groups at the non-sulfated positions (C3’ and C4’) to enhance
monomer solubility during ROMP.
Orthogonally protected disaccharide 4 was prepared from norbornene-conjugated acceptor
5[16] and glycosyl phosphate donor 6 (Scheme 3 and Supporting Information (SI) Scheme
S1). The coupling reaction utilized stoichiometric TMSOTf at −30 °C and afforded
exclusively the α-linked disaccharide 4 in 85% yield. Late stage manipulations to the
resulting disaccharide followed precedence from earlier reports.[15,17] Briefly, 4 was
subjected to the sequential addition of LiOOH and NaOH to saponify the C5’ methyl ester
and concomitantly remove the Ac and Bz protecting groups. Global O-sulfation of
disaccharide 7 using SO3•NMe3 in DMF furnished trisulfated intermediate 8 in 71% yield.
Finally, the azide group was reduced under Staudinger conditions, followed by regiospecific
N-sulfation with SO3•pyr[18] to afford tetrasulfated 3 in 54% yield over two steps.
With monomer 3 in hand, we evaluated a series of polymerization conditions. While polar
solvents were required for complete solubility of 3, unfortunately, such conditions
compromised the overall efficiency of the ROMP catalyst. Attempts at aqueous ROMP
using a water-soluble catalyst (H2IMes-poly(ethylene-glycol))(Cl)2Ru=CH(o-iPrOC4H4)[19]
led to incomplete conversion and low molecular weight polymers. Polymerization reactions
in MeOH using fast initiating catalyst (H2IMes)(Py)2(Cl)2Ru=CHPh) 9[20] produced a
similar undesired outcome. Ultimately, we found that polymerization of 3 was fully
compatible with a MeOH/(CH2Cl)2 cosolvent system at 55 °C,[10] resulting in high
conversions and good glycopolymer polydispersities. Using this cosolvent system, we then
explored the relationship between catalyst loading and polymer length. By tuning the
amount of catalyst and MeOH/(CH2Cl)2 cosolvent ratio, we synthesized a series of
glycopolymers with controlled, predictable chain lengths (10-n, where n = degree of
polymerization (DP); Table 1). Under the tested conditions, polymer lengths were limited to
45 units due to premature precipitation of polymer 10 during ROMP. All glycopolymers
were characterized at this stage by 1H NMR spectroscopy and size exclusion
chromatography multi-angle light scattering (SEC-MALS). Hydrogenation of the remaining
Bn groups using Pd(OH)2/C in a mixture of MeOH and neutral phosphate buffer[21] afforded
the desired glycopolymers (1-n) in 63–92% yield.
We next assessed the anticoagulant activities of the glycopolymers in comparison to heparin,
LMW heparin, and Arixtra. Binding of heparin to ATIII induces a conformational change
that enables ATIII to inhibit the serine proteases Factor Xa (FXa) and FIIa.[13] Protease
inhibition was measured using chromogenic substrate assays that monitor the release of p-
nitroaniline (λmax 405) from specific peptide substrates. Consistent with previous
reports,[5,22] heparin, LMWH, and Arixtra attenuated FXa activity in the presence of ATIII,
with half maximal inhibitory concentrations (IC50) of 16.5 ± 1.2, 526 ± 71, and 11.0 ± 0.1
nM, respectively (Table 2, Figure S1). To our delight, glycopolymer 1–45 showed greater
anti-FXa activity compared to the clinical anticoagulants, exhibiting an IC50 value of 5.76 ±
0.04 nM (Figure 1A, Table 2). As the polymer length decreased, we observed a significant
reduction in anti-FXa activity (IC50 = 684 ± 60 and 1470 ± 578 nM for 1–30 and 1–15,
respectively), until no activity was detected (1–10, 1–6, and 1–4; Table 2, Figure S2). We
also assessed the contribution of the glucosaminyl 3-O-sulfate modification on unit H by
comparing the activity of the glycopolymers to that of 3-O-desulfated glycopolymer 2–
155.[11]Remarkably, this single alteration in sulfation pattern abrogated the anti-FXa
activity, reaffirming the importance of 3-O-sulfation and the specificity of the polymer
interaction with ATIII (Figure 1A, Table 2). Thus, controlling the sulfation sequence and
chain length of the glycopolymer allows for the fine-tuned modulation of ATIII- mediated
inhibition at a critical junction in the blood coagulation cascade.
Oh et al. Page 3
Angew Chem Int Ed Engl. Author manuscript; available in PMC 2014 November 04.
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
FIIa is activated downstream of FXa in the coagulation cascade and facilitates blood clotting
by converting soluble fibrinogen to insoluble fibrin strands. Unlike FXa, which utilizes a
specific pentasaccharide sequence, FIIa necessitates a longer, more highly sulfated heparin
template to form an inhibitory ternary complex with ATIII.[5a,13] In agreement with this
molecular mechanism and previous reports,[5,22] heparin displayed strong anti-FIIa activity
(Figure 1B, Table 2; IC50 = 11.0 ± 0.1 nM), whereas LMWH and Arixtra had no appreciable
activity (Table 2, Figure S1). Notably, we found that glycopolymer 1–45 was 100-fold more
potent than heparin at inhibiting FIIa (IC50 = 114 ± 1 pM), which is likely due to a greater
number of active tetrasulfated motifs and increased polymer length. These results are
exciting because they demonstrate that synthetic glycopolymers can be designed to surpass
the biological activity of natural glycosaminoglycans. Glycopolymer 1–30 was also active in
this assay (IC50 = 577 ± 31 nM), and as expected, the shorter polymers (1–15, 1–10, 1–6,
and 1–4) and trisulfated glycopolymer (2–155) showed no significant activity (Figures 1B
and S2, Table 2).
To assess potential interactions with PF4, we evaluated the ability of PF4 to neutralize the
anti-FIIa activity of glycopolymers 1–45 and 1–30. PF4 was added to the glycopolymers or
heparin (0.5 – 500 µg/mL) in the presence of ATIII and excess FIIa, and FIIa activity was
measured using the same chromogenic assay. Both heparin and glycopolymer 1–45
interacted strongly with PF4, consistent with reports that longer polysaccharides are more
likely to engage PF4.[4,23] However, the anti-FIIa activity of glycopolymer 1–30 was only
partially neutralized by PF4 (Figure S3), indicating PF4 reactivity associated with HIT can
be minimized to some extent by modulating the polymer length.
Finally, we examined the ex vivo clotting times of the glycopolymers, with comparison to
clinical anticoagulants, using human plasma samples. As the presence of other proteins in
complex serum can interfere with anticoagulant activity, this assay represents a more
stringent test of anticoagulant efficacy. We measured the activated partial thromboplastin
time (APTT) and prothrombin time (PT) of each compound to determine its ability to inhibit
blood clotting via the intrinsic and/or extrinsic pathways of the coagulation cascade,
respectively.[24] Heparin increased both the APTT and PT for clotting compared to the
saline control (Table 2), whereas LMWH and Arixtra at the same concentration increased
only the APTT. Notably, the APTT of the glycopolymers could be controlled by varying the
polymer length, with a minimum of 10 disaccharide epitopes (1–10) required to prolong the
APTT. A slight increase to 15 units (1–15) endowed the polymer with APTT properties
similar to Arixtra, whereas the PT was not appreciably altered in either case. Glycopolymers
1–30 and 1–45 modulated both the APTT and PT, in agreement with their ability to inhibit
FXa and FIIa in vitro. Remarkably, tuning of the polymer structure produced anticoagulants
with unique hybrid properties. While the APTTs of 1–30 and 1–45 were comparable to those
of LMWH and Arixtra, their PTs more closely resembled that of heparin. Lastly, as
expected, trisulfated glycopolymer 2–155 showed no appreciable change in APTT or PT,
reinforcing the importance of the 3-O sulfate modification and the potential to tune the
selectivity of the glycopolymers toward specific heparin/HS-binding proteins by modulating
the sulfation pattern. Overall, the ex vivo profile of the glycopolymers not only validates
their efficacy in human plasma, but also their ability to replicate the activity profiles of the
clinical anticoagulants. Moreover, we find that fine-tuning of the glycopolymer structure can
lead to agents with novel properties not found in naturally occurring oligo- and
polysaccharides.
Heparin has been used clinically as an anticoagulant since 1935 for treatment and prevention
of deep vein thrombosis during surgery, blood transfusion, and renal dialysis. Recent
contamination issues associated with animal-sourced heparin have highlighted the
importance of developing safer, more homogeneous alternatives to unfractionated heparin.
Oh et al. Page 4
Angew Chem Int Ed Engl. Author manuscript; available in PMC 2014 November 04.
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
H
H
M
I Author M
anuscript
While structurally-defined oligosaccharides such as Arixtra offer a valuable solution to this
problem, they are notoriously challenging and expensive to synthesize. Here we have
reported the design and expedient synthesis of homogeneously sulfated glycopolymers
based on a tetrasulfated disaccharide motif found in heparin. We demonstrate that these
glycopolymers have potent anticoagulant activity, inhibiting the serine proteases FXa and
FIIa through potentiation of ATIII and replicating the ex vivo plasma clotting activity of the
clinical anticoagulants heparin, LMWH, and Arixtra. Most interestingly, we found that
systematic alterations in the glycopolymer length and sulfation pattern enabled the fine-
tuned modulation of their anticoagulant activity, leading to the creation of new agents with
unique hybrid activities distinct from those of both natural and synthetic
glycosaminoglycans. These findings demonstrate the potential of this neoglycopolymer
approach to control medicinally significant glycosaminoglycan-mediated events and raise
the prospect of developing a novel class of anticoagulants through systematic explorations
into the glycopolymer structure.
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Figure 1.
Tetrasulfated glycopolymers (1–15, 1–30, 1–45) inhibit the ATIII-mediated (A) FXa and (B)
FIIa activity in a length and sulfation-dependent manner. Chromogenic substrate assays
were used to measure coagulation factor activity in the presence of ATIII and glycopolymer.
Data represent the mean ± standard deviation for n=3 experiments. See Table 2 for IC50
values.
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Scheme 1.
Chemical structures of Arixtra, Org31550, and synthetic glycopolymers 1 and 2.
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Scheme 2.
Retrosynthesis of glycopolymer 1 from orthogonally-protected disaccharide 3.
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Scheme 3.
Synthesis of tetrasulfated heparin glycopolymer 1a
aConditions: (a) TMSOTf, CH2Cl2, −30 °C, 85%. (b) 0.7 M LiOH, H2O2, 25 °C; MeOH, 4
M NaOH, 25 °C, 82% over two steps. (c) SO3•TMA, DMF, 60 °C, 71%. (d) PMe3, THF, 25
°C, quant. (e) SO3•pyr, pyr/Et3N, 60 °C, 54% over two steps. (f) MeOH:(CH2Cl)2, 55 °C.
(g) Pd(OH)2/C, 1 atm H2, MeOH, phosphate buffer (pH 7.4), 63–92%.
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Table 2
Biological Activity of Heparin Glycopolymers
Polymer Anti-FXa
IC50 (nM)
Anti-FIIa
IC50 (nM)
APTT[a]
(s)
PT[a]
(s)
1–4 >2000 >2000 032.5 ± 0.3 13.2 ± 0.1
1–6 >2000 >2000 032.2 ± 0.2 13.2 ± 0.3
1–10 >2000 >2000 059.6 ± 0.3 15.8 ± 0.4
1–15 1470 ± 578 >2000 082.9 ± 0.6 23.4 ± 1.9
1–30 684 ± 60 577 ± 31 100.8 ± 0.6 50.8 ± 6.3
1–45 5.76 ± 10−2 0.114 ± 10−4 119.4 ± 0.5 52.2 ± 7.8
2–155 >2000 >2000 046.1 ± 0.4 12.7 ± 0.1
None >2000 >2000 031.2 ± 0.3 13.3 ± 0.1
Heparin 16.5 ± 1.2 11.0 ± 0.1 >180 84.2 ± 18.
LMWH 526 ± 71 >2000 0.117 ± 3.0 14.8 ± 0.2
Arixtra 11.0 ± 0.1 >2000 078.3 ± 0.4 15.1 ± 0.3
[a]150 µg/mL compound in citrated human plasma, n=3
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